Genfit S.A. (GNFT)
$5.97+0.00%Close
BUYBEAR · day 1
Key stats
- Market cap
- $297M
- Beta
- 0.87
- P/E (TTM)
- 266.26
- 1W
- -3.71%
- 1M
- +6.23%
- vs SPY 1W
- -3.57%
- vs SPY 1M
- +3.72%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 8
- VALUE
- 0
- GROWTH
- 43
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC1.3%
REV YoY-
ROE2.2%
EPS YoY-
ROA1.0%
GROSS100
OP5
NET2
[VALUATION]
P/E TTM266.26
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B5.80
P/FCF-
EV/EBITDA45.30
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E89.76
ALTMAN Z-
CURR RATIO1.23
ND/EBITDA-
BETA0.87
Company news
FAQ
- What is LOPJLB’s current signal on GNFT?
- LOPJLB’s latest quantitative signal on Genfit S.A. (GNFT) is BUY in a BEAR regime. Signals are updated daily.
- What market regime is GNFT in?
- Genfit S.A. (GNFT) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Genfit S.A. (GNFT) do?
- Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developi…